Combined MET and PD-L1 inhibition shows promise in MET-driven metastatic papillary renal cancer
Advanced papillary renal cancer (PRC) has a poor prognosis with few treatment options available. Approximately 30% of patients with this disease present alterations in the MET gene that encodes a hepatocyte growth factor ...
Feb 28, 2023
0
2